MLTX - MoonLake Immunotherapeutics GAAP EPS of -$0.31

2023-03-20 09:03:14 ET

• MoonLake Immunotherapeutics press release ( NASDAQ: MLTX ): Q4 GAAP EPS of -$0.31.
• Cash cash and equivalents of $72.1M
• Research and development expenses for the fourth quarter ended December 31, 2022 were $11.4 million, compared to $9.0 million in the previous quarter.
• General and administrative expenses for the fourth quarter ended December 31, 2022 were $5.3 million, compared to $5.7 million in the previous quarter.

• Net loss for the year ended December 31, 2022 was $64.5 million compared to $53.6 million for the period from March 10, 2021 (inception) to December 31, 2021.

• As of December 31, 2022, there were 53.3 million fully diluted ordinary shares outstanding.

For further details see: